Toes-Zoutendijk E. Interval cancers after a negative faecal immunochemical test in the first screening round in the Netherlands: results for two cut-off levels. UEG Week 2018, LB14.
Europese Commissie keurt risankizumab (Skyrizi) goed voor behandeling matig tot ernstig actieve colitis ulcerosa
okt 2024 | IBD